当前位置:首页 - 行情中心 - 圣达生物(603079) - 财务分析 - 利润表

圣达生物

(603079)

  

流通市值:30.16亿  总市值:33.31亿
流通股本:1.71亿   总股本:1.89亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入400,730,585.4203,225,651.02827,401,959.68608,870,278.32
  营业收入400,730,585.4203,225,651.02827,401,959.68608,870,278.32
二、营业总成本353,802,598.39174,454,492.13775,052,391.23577,385,792.61
  营业成本289,224,241.02144,500,426.11651,452,036.05485,917,821.02
  税金及附加5,098,878.782,634,795.2711,105,308.877,426,983.96
  销售费用6,857,379.972,668,964.5414,645,144.210,092,998.05
  管理费用31,410,388.5314,864,798.7563,843,516.0549,669,221.61
  研发费用23,017,412.6110,162,625.2443,762,465.0929,025,818.97
  财务费用-1,805,702.52-377,117.78-9,756,079.03-4,747,051
  其中:利息费用429,308.17250,833.342,076,164.121,099,956.42
  其中:利息收入1,578,311.31644,8757,951,083.854,109,259.65
三、其他经营收益
  加:公允价值变动收益-958.36-756.61,210.562,068.04
  加:投资收益754,511.08449,777.4723,379.083,015,295.08
  资产处置收益-86,177.7-86,177.7145,968.82-
  资产减值损失(新)-933,206.09-3,243,969.71-10,643,054.89-5,972,851.85
  信用减值损失(新)163,447.07-627,119.21-5,462,103.38-6,655,326.71
  其他收益3,525,750.152,370,433.869,451,253.946,350,545.46
四、营业利润50,351,353.1627,633,346.9346,566,222.5828,224,215.73
  加:营业外收入155,885.39104,456.4911,171,213.8211,170,564.99
  减:营业外支出241,710.81,420.428,652,161.834,187,764.43
五、利润总额50,265,527.7527,736,38349,085,274.5735,207,016.29
  减:所得税费用9,769,969.544,317,471.6411,827,625.687,797,813.78
六、净利润40,495,558.2123,418,911.3637,257,648.8927,409,202.51
(一)按经营持续性分类
  持续经营净利润40,495,558.2123,418,911.3637,257,648.8927,409,202.51
(二)按所有权归属分类
  归属于母公司股东的净利润37,805,384.421,709,484.8529,424,490.0521,679,027.87
  少数股东损益2,690,173.811,709,426.517,833,158.845,730,174.64
  扣除非经常损益后的净利润35,058,781.819,717,813.2722,464,100.779,613,762.88
七、每股收益
  (一)基本每股收益0.220.130.170.13
  (二)稀释每股收益0.220.130.170.13
九、综合收益总额40,495,558.2123,418,911.3637,257,648.8927,409,202.51
  归属于母公司股东的综合收益总额37,805,384.421,709,484.8529,424,490.0521,679,027.87
  归属于少数股东的综合收益总额2,690,173.811,709,426.517,833,158.845,730,174.64
公告日期2025-08-262025-04-282025-04-282024-10-26
审计意见(境内)标准无保留意见
TOP↑